Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.
A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.
This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.
This fact sheet reviews common symptoms associated with polycythemia vera (PV) and how a patient may address them, along with an overview of more serious symptoms that require medical attention.
Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.
Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.
Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.
A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.
Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
NCCN released its newest Clinical Practice Guidelines in Oncology. These guidelines will assist with preventive, diagnostic, and treatment decisions for patients with myelofibrosis, as well as the other myeloproliferative neoplasms, essential thrombocythemia and PV.
Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.
Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.
This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.
A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.
Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New InsightsApril 19, 2017
Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.
Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.
In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.
Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.
Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.
This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.
The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.
Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.
Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|